Educating Groups Influencing Generic Drug Use

教育影响仿制药使用的群体

• 批准号: 9340998
• 负责人: ILENE HARRIS
• 金额: $ 25万
• 依托单位: AUBURN UNIVERSITY AT AUBURN
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-15 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9340998
• 关键词: Educating; Groups; Influencing; Generic; Drug

Project Abstract Spending on prescription drugs in the U.S. has risen 114% since 2000. One way to combat rising prescription drug costs is to encourage use of generic drugs. Just considering U.S. Medicare and Medicaid programs, an estimated $89 billion could be saved over the next decade through expanded generic drug use. While the cost- savings of generics is clear, generic drug market penetration varies across classes of drugs, by prescribers, and by geographic location. Evidence shows that generic drug use is largely impacted by certain key groups' behaviors and perceptions towards generic drugs. While believed to be influential, the extent of each groups influence is heterogeneous and dependent on factors such as experiences and perceptions with generic drugs. Thus, effective educational efforts to target all types of barriers that may limit generic drug use are a critical need. The purpose of the proposed research is to understand roles of key groups and the extent of their influence on generic drug use in order to provide additional and effective educational outreach to meet their informational needs. To this end, we will use a mixed-methods approach to address three study aims: 1) to study the key groups influencing generic drug use in the U.S. and to determine the nature and extent of their influence; 2) to determine the key groups' informational needs regarding generic drugs and establish the current and desired means by which these key groups receive healthcare-related educational material; and 3) to develop, test, and revise educational materials to address key groups' informational needs regarding generic drugs. The six a priori defined key groups include patients/caregivers, prescribers, pharmacists, insurance formulary managers, state health policy makers, and pharmaceutical manufacturers. We will determine the nature and extent of each groups influence using systematic review combined with innovative analyses of multiple publicly available datasets. Qualitative key informant interviews will develop profiles of informational needs for generic drugs overall and for specific drug groups that have unique properties. Developmental panels combined with key informant interviews and surveys will develop and refine educational materials. The expected outcomes of this study are provision of information, strategies, and educational materials to overcome barriers to generic drug use in the U.S.

项目摘要 自 2000 年以来，美国处方药支出增长了 114%。应对处方药增加的一种方法 药品费用是为了鼓励使用仿制药。仅考虑美国医疗保险和医疗补助计划， 据估计，通过扩大仿制药的使用，未来十年可节省 890 亿美元。虽然成本- 仿制药的节省是显而易见的，仿制药市场渗透率因处方者的不同药物类别而异， 并按地理位置。有证据表明，仿制药的使用在很大程度上受到某些关键群体的影响 对仿制药的行为和看法。虽然每个群体被认为具有影响力，但其范围 影响是异质性的，并且取决于仿制药的经验和看法等因素。 因此，针对可能限制仿制药使用的所有类型障碍的有效教育工作至关重要 需要。拟议研究的目的是了解关键群体的作用及其影响的程度 影响仿制药的使用，以便提供额外和有效的教育外展以满足他们的需要 信息需求。为此，我们将使用混合方法来实现三个研究目标：1） 研究影响美国仿制药使用的关键群体，并确定其性质和程度 影响; 2) 确定重点人群关于仿制药的信息需求，并建立 这些关键群体接受医疗保健相关教育材料的当前和期望的方式；和 3) 开发、测试和修订教育材料，以满足关键群体对通用药物的信息需求 药物。六个预先定义的关键群体包括患者/护理人员、处方者、药剂师、保险人 处方管理人员、国家卫生政策制定者和药品制造商。我们将确定 通过系统审查与创新分析相结合，了解每个群体影响的性质和程度 多个公开可用的数据集。定性关键知情人访谈将形成信息概况 对总体仿制药和具有独特特性的特定药物组的需求。发育性 小组讨论与关键知情者访谈和调查相结合将开发和完善教育材料。这 这项研究的预期成果是提供信息、策略和教育材料 克服美国仿制药使用的障碍

项目成果

Patient and caregiver opinions about an FDA-developed generic drug educational handout: A pilot cross-sectional survey.

患者和护理人员对 FDA 开发的仿制药教育讲义的看法：一项试点横断面调查。

• DOI: 10.1016/j.japh.2020.10.019
• 发表时间: 2021
• 期刊: Journal of the American Pharmacists Association : JAPhA
• 作者: Hohmann,NatalieS;Poudel,Nabin;Garza,KimberlyB;Surry,Daniel;Hansen,RichardA;Harris,Ilene;Kiptanui,Zippora;Oguntimein,Oluwamurewa;Frost,MitchellM;Qian,Jingjing
• 通讯作者: Qian,Jingjing

Association between Higher Generic Drug Use and Medicare Part D Star Ratings: An Observational Analysis.

较高仿制药使用与医疗保险 D 部分星级评级之间的关联：观察分析。

• DOI: 10.1016/j.jval.2018.03.005
• 发表时间: 2018
• 期刊: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
• 作者: Hohmann,Natalie;Hansen,Richard;Garza,KimberlyB;Harris,Ilene;Kiptanui,Zippora;Qian,Jingjing
• 通讯作者: Qian,Jingjing

Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing.

• DOI: 10.1002/pds.4224
• 发表时间: 2017-07
• 期刊: Pharmacoepidemiology and drug safety
• 影响因子: 2.6
• 作者: Qian J;Hansen RA;Surry D;Howard J;Kiptanui Z;Harris I
• 通讯作者: Harris I

Communicating benefits and risks of generic drugs to consumers: Patient and caregiver opinions of two FDA-developed educational materials.

向消费者传达仿制药的益处和风险：患者和护理人员对 FDA 开发的两份教育材料的意见。

• DOI: 10.1016/j.sapharm.2019.01.013
• 发表时间: 2019
• 期刊: Research in social & administrative pharmacy : RSAP
• 作者: Hohmann,NatalieS;Garza,KimberlyB;Surry,Daniel;Hansen,RichardA;Harris,Ilene;Kiptanui,Zippora;Oguntimein,Oluwamurewa;Frost,MitchellM;Qian,Jingjing
• 通讯作者: Qian,Jingjing